Clinical and hemodynamic efficacy ofprestarium and its role in the treatment of chronic pulmonary heart


Cite item

Full Text

Abstract

Aim. To assess clinical efficiency and safety of ACE inhibitor prestarium (Servier, France) with specification of its effects on central and pulmonary hemodynamics, hepatic blood flow, indications in patients with chronic pulmonary heart (CPH).
Material and methods. 42 patients with chronic obstructive bronchitis (COB) complicated by CPH
entered the trial. The patients were divided into two groups. Group 1 (n = 26) received standard therapy plus prestarium (2-4 mg/day), group 2 (n = 16) received only standard combined therapy. The
examinees have undergone ultrasonic investigation of the heart and liver in Doppler modes, ECG
monitoring, examination for external respiration function, lipid peroxidation activity, antioxidant blood
defense.
Results. Group 1 demonstrated earlier positive response. It was found that improvement in functional
class of cardiac failure induced by prestarium and less frequent episodes of arrhythmia directly correlated. Positive changes were stated in central and hepatic hemodynamics, systolic pressure in the pulmonary artery lowered more significantly than in the control group.
Conclusion. If COB patients have symptoms of right ventricular failure, they are recommended to take
prestarium in a daily dose 0.004g for 4 weeks to improve intracardiac and hepatic hemodynamics, reduce systolic pressure in the pulmonary artery and number of prognostically unfavourable arrhythmic
episodes.

References

  1. Авдеев С. Н., Соколов А. С, Чучалин А. Г. Применение отечественного симпатомиметика вентокола при тяжелом обострении хронической обструктивной болезни. Пульмонология 1999; 2: 24-30.
  2. Федосова Н. Н., Оферкин А. И., Крейнес В. М. и др. Взаимосвязь электрофизиологических параметров сердца с газовым составом крови и показателями гемодинамики у больных хроническим обструктивным бронхитом. Тер. арх. 2001; 3:37-40.
  3. Казанбиев Н. К. Декомпенсированное легочное сердце. Актуальные вопросы лечения. Клин. мед. 1996; 4: 11 - 14.
  4. Багирова Г. Г., Баталина М. В. Лечение хронической сердечной недостаточности у больных с митральными и аортальными пороками сердца ревматической этиологии. Тер. арх. 2000; 9: 63-66.
  5. Бойцов С. А. Хроническая недостаточность кровообращения. Современные аспекты лечения. Гедеон Рихтер в СНГ 2000; 1: 24-27.
  6. Мартынов А. И., Степура О. Б., Гаджиев А. Н. и др. Применение ингибиторов ангиотензин-превращающего фермента при артериальной гипертонии (по материалам XXI-XXII конгрессов европейского общества кардиологов). Клин. мед. 2001; 6: 71-73.
  7. Butorov [. V., Usatai A., Bodrug N. I., Shkolinik M. Tratamentue dereglarilor hemodinamicii in bronhopneumopatiile obstructive cronice. (Recomandari metodice). Chisinau, 1998.

Copyright (c) 2003 Korneichuk N.N., Butorov I.V., Verbitsky O.N., Butorova V.G., Paraska V.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

© 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies